Protara Therapeutics, Inc. (TARA)
3.82
+0.03
(+0.79%)
USD |
NASDAQ |
Sep 11, 16:00
3.89
+0.07
(+1.83%)
Pre-Market: 08:35
Protara Therapeutics Enterprise Value : 85.96M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 85.96M |
| September 10, 2026 | 84.18M |
| September 09, 2026 | 86.55M |
| September 08, 2026 | 90.09M |
| September 04, 2026 | 93.05M |
| September 03, 2026 | 94.82M |
| September 02, 2026 | 93.05M |
| September 01, 2026 | 90.68M |
| August 31, 2026 | 88.32M |
| August 28, 2026 | 85.96M |
| August 27, 2026 | 96.00M |
| August 26, 2026 | 91.27M |
| August 25, 2026 | 94.82M |
| August 24, 2026 | 88.91M |
| August 21, 2026 | 87.73M |
| August 20, 2026 | 90.68M |
| August 19, 2026 | 94.23M |
| August 18, 2026 | 95.41M |
| August 17, 2026 | 95.41M |
| August 14, 2026 | 94.82M |
| August 13, 2026 | 93.05M |
| August 12, 2026 | 90.09M |
| August 11, 2026 | 91.27M |
| August 10, 2026 | 103.09M |
| August 07, 2026 | 103.68M |
| Date | Value |
|---|---|
| August 06, 2026 | 102.50M |
| August 05, 2026 | 96.59M |
| August 04, 2026 | 97.18M |
| August 03, 2026 | 94.82M |
| July 31, 2026 | 91.86M |
| July 30, 2026 | 98.36M |
| July 29, 2026 | 85.36M |
| July 28, 2026 | 93.05M |
| July 27, 2026 | 98.95M |
| July 24, 2026 | 97.77M |
| July 23, 2026 | 98.95M |
| July 22, 2026 | 101.32M |
| July 21, 2026 | 101.91M |
| July 20, 2026 | 100.73M |
| July 17, 2026 | 102.50M |
| July 16, 2026 | 101.32M |
| July 15, 2026 | 103.68M |
| July 14, 2026 | 101.91M |
| July 13, 2026 | 107.23M |
| July 10, 2026 | 115.50M |
| July 09, 2026 | 108.41M |
| July 08, 2026 | 103.09M |
| July 07, 2026 | 112.54M |
| July 06, 2026 | 101.32M |
| July 02, 2026 | 100.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 13.27M |
| Summit Therapeutics, Inc. | 13.25B |
| Kezar Life Sciences, Inc. | -11.12M |
| Clene, Inc. | 58.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.67M |
| Total Expenses (Quarterly) | 21.67M |
| EPS Diluted (Quarterly) | -0.3552 |
| Earnings Yield | -35.44% |
| Normalized Earnings Yield | -35.44 |